宁脉潜阳颗粒治疗难治性高血压临床分析
|
摘要
目的观察宁脉潜阳中药颗粒治疗难治性高血压患者肝阳上亢证的临床疗效。方法病例选自2017年1月―2018年1月于该院心内科住院患者,研究对象及家属均知情同意,并通过了伦理委员会的批准。将96例诊断为难治性高血压病肝阳上亢证的病人随机分为两组,其中对照组给予西药降压治疗,治疗组在西药降压治疗基础上加服宁脉潜阳颗粒,每组48例,治疗1个月后对两组中医症状和血压控制方面比较疗效。结果治疗组患者治疗后的血压降压幅度SBP(136.61±8.62)mmHg、DBP(77.85±5.31)mmHg较治疗前比较有所改善,显著优于对照组治疗后的血压降压幅度,差异有统计学意义(t=4.326,8.365,P<0.05);治疗组难治性高血压患者治疗后的血压总达标率为89.58%,显著高于对照组患者血压总达标率为72.91%,差异有统计学意义(χ~2=16.668,P<0.05);治疗一月后中医症候积分均较前有所改善,治疗组总有效率为91.66%,对照组总有效率81.25%,组间比较,差异有统计学意义(χ~2=4.365,P<0.05)。结论针对难治性高血压疾病采用宁脉潜阳颗粒进行治疗的临床效果显著,值得临床推广。
Objective To observe the clinical efficacy of Ningmai Qianyang Traditional Chinese Medicine Granule in treating liver-yang hyperactivity syndrome in patients with refractory hypertension. Methods The patients were enrolled in the Department of Cardiology of the hospital from January 2017 to January 2018. The subjects and their families were informed and approved by the Ethics Committee. 96 patients diagnosed as refractory hypertension with liver-yang hyperactivity syndrome were randomly divided into two groups. The control group was given western medicine antihypertensive treatment. The treatment group was given Ningmai Qianyang granules on the basis of western medicine antihypertensive treatment, with 48 cases each. After one month of treatment, the two groups were more effective in controlling TCM symptoms and blood pressure. Results The blood pressure-reducing amplitudes of SBP(136.61±8.62) mmHg and DBP(77.85±5.31) mmHg in the treatment group were improved compared with those before treatment, which was significantly better than that of the control group, which was statistically significant(t=4.326, 8.365, P<0.05). The total compliance rate of blood pressure in the treatment group was 89.58%, which was significantly higher than the control group. The blood pressure was up to 72.91%, with statistical significance; after treatment(χ~2=16.668, P<0.05), the scores of TCM symptoms were improved compared with the previous ones. The total effective rate of the treatment group was 91.66%, and the total effective rate of the control group was 81.25%, there was a significant difference between groups(χ~2=4.365, P <0.05). Conclusion The clinical effect of treatment of refractory hypertensive disease with Ningmai Qianyang Granule is significant and worthy of clinical promotion.
Objective To observe the clinical efficacy of Ningmai Qianyang Traditional Chinese Medicine Granule in treating liver-yang hyperactivity syndrome in patients with refractory hypertension. Methods The patients were enrolled in the Department of Cardiology of the hospital from January 2017 to January 2018. The subjects and their families were informed and approved by the Ethics Committee. 96 patients diagnosed as refractory hypertension with liver-yang hyperactivity syndrome were randomly divided into two groups. The control group was given western medicine antihypertensive treatment. The treatment group was given Ningmai Qianyang granules on the basis of western medicine antihypertensive treatment, with 48 cases each. After one month of treatment, the two groups were more effective in controlling TCM symptoms and blood pressure. Results The blood pressure-reducing amplitudes of SBP(136.61±8.62) mmHg and DBP(77.85±5.31) mmHg in the treatment group were improved compared with those before treatment, which was significantly better than that of the control group, which was statistically significant(t=4.326, 8.365, P<0.05). The total compliance rate of blood pressure in the treatment group was 89.58%, which was significantly higher than the control group. The blood pressure was up to 72.91%, with statistical significance; after treatment(χ~2=16.668, P<0.05), the scores of TCM symptoms were improved compared with the previous ones. The total effective rate of the treatment group was 91.66%, and the total effective rate of the control group was 81.25%, there was a significant difference between groups(χ~2=4.365, P <0.05). Conclusion The clinical effect of treatment of refractory hypertensive disease with Ningmai Qianyang Granule is significant and worthy of clinical promotion.
引文
[1]法国高血压协会.关于难治性高血压治疗的专家共识[J].Journal of Hypertension advance online publication,2016,10(2):122.
[2]耿红玉,貢歌,李妍妍.难治性高血压的治疗进展[J].中华老年心脑血管病杂志,2015,17(9):987-989.
[3]周仲瑛.中医内科学[M].北京:中国中医药出版社, 2017:315.
[4]王帅.难治性高血压的临床研究[D].上海:上海交通大学,2015.
[5]陈改玲,乔素玲.难治性高血压的诊治对策[J].中国医刊,2016,51(12):12-14.
[6]柯元南.关注难治性高血压[J].中国医刊,2016,51(12):4-6.
[7]孙东东,王佐广,温绍君.难治性高血压临床治疗进展[J].心肺血管病杂志,2017,36(03):182-184,189.
[8]尚晓斌.难治性高血压最新治疗研究进展[J].系统学,2017,2(9):159-161.
[9]刘子安,宫海滨,李春梅,等.169例难治性高血压病因回顾性分析[J].中国卫生标准管理,2017,8(25):8-9.
[10]姚兑海.难治性高血压的病因及治疗进展研究[J].临床医药文献电子杂志,2017,4(A1):19 982-19 983.
[11]雷雅婷.难治性高血压治疗方案新进展[J].临床医学,2016,29(11):22-24.
[12]王雪芹,曹春永.难治性高血压治疗的研究进展[J].临床医药文献电子杂志,2018,5(7):177.
[13]宋志欣.难治性高血压中医证候学分布及相关性研究[D].长春:长春中医药大学,2015
[14]李雨真.基础西药结合中医辨证治疗难治性高血压的临床观察[J].中国实用医药.2018,13(15):123-124.
[15]曹曙波.中国民族民间医药[J].2013,2(4):83.
[2]耿红玉,貢歌,李妍妍.难治性高血压的治疗进展[J].中华老年心脑血管病杂志,2015,17(9):987-989.
[3]周仲瑛.中医内科学[M].北京:中国中医药出版社, 2017:315.
[4]王帅.难治性高血压的临床研究[D].上海:上海交通大学,2015.
[5]陈改玲,乔素玲.难治性高血压的诊治对策[J].中国医刊,2016,51(12):12-14.
[6]柯元南.关注难治性高血压[J].中国医刊,2016,51(12):4-6.
[7]孙东东,王佐广,温绍君.难治性高血压临床治疗进展[J].心肺血管病杂志,2017,36(03):182-184,189.
[8]尚晓斌.难治性高血压最新治疗研究进展[J].系统学,2017,2(9):159-161.
[9]刘子安,宫海滨,李春梅,等.169例难治性高血压病因回顾性分析[J].中国卫生标准管理,2017,8(25):8-9.
[10]姚兑海.难治性高血压的病因及治疗进展研究[J].临床医药文献电子杂志,2017,4(A1):19 982-19 983.
[11]雷雅婷.难治性高血压治疗方案新进展[J].临床医学,2016,29(11):22-24.
[12]王雪芹,曹春永.难治性高血压治疗的研究进展[J].临床医药文献电子杂志,2018,5(7):177.
[13]宋志欣.难治性高血压中医证候学分布及相关性研究[D].长春:长春中医药大学,2015
[14]李雨真.基础西药结合中医辨证治疗难治性高血压的临床观察[J].中国实用医药.2018,13(15):123-124.
[15]曹曙波.中国民族民间医药[J].2013,2(4):83.